On Wednesday, Shares of Barrick Gold Corporation (USA) (NYSE:ABX), added 3.43% and closed at $15.98 in the last trading session. The last trading range of the stock ranges between $15.53 and $16.03. Barrick Gold Corporation (ABX.TO)(ABX.TO) (Barrick or the “company”) recently declared the resumption of normal operations at the Veladero mine in Argentina following approval from San Juan provincial authorities.
Operations at the mine were suspended on September 15, a week after falling ice damaged a pipe carrying process solution in the leach pad area, causing some material to leave the leach pad. This material, mainly crushed ore saturated with process solution, was contained on the mine site and returned to the leach pad. Extensive water monitoring in the area has confirmed the incident did not result in any environmental impacts. The company has accomplished a series of remedial works required by provincial authorities designed to prevent such an incident from reoccurring, counting increasing the height of the perimeter berms that surround the leach pad.
Chevron Corporation (NYSE:CVX), jumped 0.95% and closed at $102.23 in the last trading session. The last trading range of the stock ranges between $101.75 and $102.86. The company’s Market capitalization is $190.64 Billion with the total Outstanding Shares of 1.89 Billion. Chevron U.S.A. Inc. ( NYSE : CVX ) declared recently the launch of its aFANity™ Rewards Program, a sports-themed rewards program available to residents of Alabama, Arizona, California, Florida, Georgia, Idaho, Louisiana, Mississippi, Nevada, New Mexico, Oregon, Tennessee, Texas, Utah, Washington and Wyoming. Eligible participants can sign up as members to begin earning points starting on October 1. They can redeem those points for prizes such as football tickets, autographed memorabilia, officially licensed team gear, and unique once-in-a-lifetime experiences with their favorite teams.
Sports fans will have a chance to reward themselves with exciting gear and memorabilia that fit their passion. Members earn points just for signing up with aFANity™ and can earn additional points through activities, like connecting their social media accounts, connecting their Chevron and Texaco Techron Advantage™ Credit Card, using their connected card at Chevron and Texaco stations in the participating areas, and even attending Chevron-sponsored football games.
Opko Health Inc. (NASDAQ:OPK), gained 1.42% and closed at $10.74 in the last trading session. The last trading range of the stock ranges between $10.66 and $10.91. During the 52-week trading session the minimum price at which share price traded, registered at $7.12 and reached to max level of $11.85. OPKO Health, Inc. (OPK), declares the appointment of Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as of October 3, 2016. GeneDx, part of OPKO’s BioReference Laboratories partner, specializes in genetic testing for rare hereditary disorders.
Dr. Solomon is a pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions. He is a leader in integrating cutting-edge technologies to better manage health and disease. He most recently served as Chief of the Division of Medical Genomics at the Inova Translational Medicine Institute, a clinical research institute dedicated to putting genomic medicine into action.
“We are very proud to have Dr. Solomon join the OPKO Health team as the new leader of our GeneDx division, a world-class genomics laboratory. A recognized leader in his field, Dr. Solomon’s expertise in genomics and genetics will be of great value as we continue to leverage leading technologies to build and expand GeneDx’s global role in diagnostic and laboratory services. His passion for finding answers for patients and clinicians and his talent and experience in the integration of genomics into the practice of medicine will enhance the numerous and diverse communities in the U.S. and worldwide that benefit from the outstanding diagnostic services our laboratories offer,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories.